Aj Silver, Senior Vice President Finance at CRISPR Therapeutics

Aj Silver

Senior Vice President Finance at CRISPR Therapeutics | Suffolk County, Massachusetts, United States

Profile last verified October 2026
Biotechnology Verified Profile Suffolk County, Massachusetts, United States University of Connecticut School of Business
Verified

Work Email

***@crisprtx.com

Last verified May 2026

Personal Email

***@gmail.com

Personal • High Confidence

Phone Number

508*****

United States • Mobile

Free account · No credit card · 5 profiles/month

Aj Silver Socials
Aj Silver Work Experience

Senior Vice President Finance at CRISPR Therapeutics in January 2025 - Present

Vice President Corporate Finance at CRISPR Therapeutics in January 2023 - March 2025

Executive Director, Finance & Accounting at CRISPR Therapeutics in January 2021 - March 2023

See more See less

Senior Director, Reporting & Technical Accounting at CRISPR Therapeutics in February 2020 - January 2021

Director, Reporting & Technical Accounting at CRISPR Therapeutics in October 2018 - February 2020

Senior Manager Assurance Services at E&Y in February 2011 - October 2018

Financial Analyst at Summit Partners in August 2010 - February 2011

Public Accountant at Ernst & Young in August 2007 - August 2010

Aj Silver Education

University of Connecticut School of Business, MSA, November 2026

Boston College Carroll School of Management, BS, November 2026

About Aj Silver’s Current Company
CRISPR Therapeutics

Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.

Discover more about CRISPR Therapeutics
Aj Silver’s Colleagues
Hannah Nierle

Hannah Nierle

Greater Boston

Clinical Trial Manager at CRISPR Therapeutics

Clinical Trial Manager at CRISPR Therapeutics
(August 2025 – Present)

Kiera Fallon

Kiera Fallon

Boston, Massachusetts, United States

Research Associate at CRISPR Therapeutics || MBA Candidate at Questrom School of Business

Research Associate II at CRISPR Therapeutics
(June 2024 – Present)

Sammy Hankaoui

Sammy Hankaoui

Greater Boston

Cell Therapy at CRISPR Therapeutics || MBA Candidate at WPI

Cell Therapy at CRISPR Therapeutics
(July 2023 – Present)

Q

Qichen

Boston, Massachusetts, United States

Scientist at CRISPR Therapeutics

Scientist, CRISPR-X at CRISPR Therapeutics
(June 2024 – Present)

MD

Marylee Dequeant

Greater Boston

Executive Director, Head of In Vivo Research | Immuno-Oncology | Cell and Gene Therapy | CRISPR | LNP Delivery | CAR-T | CTA and IND Strategy | Cross-Functional Leadership | Regulatory Interactions | AAV | Liver | Eye |

Head of In Vivo Research, Executive Director, and Immuno-Oncology Lead at CRISPR Therapeutics
(July 2024 – Present)

Aamir Mir

Aamir Mir

Cambridge, Massachusetts, United States

Senior Director at CRISPR Therapeutics

Senior Director, CRISPR-X at CRISPR Therapeutics
(Jul 2025 – Present)

Search similar profiles
Frequently asked questions about Aj Silver

What is Aj Silver email address?

Email Aj Silver at [email protected] and [email protected]. This email is the most updated Aj Silver's email found in 2026.

What is Aj Silver phone number?

Aj Silver phone number is 5084501376.

How to contact Aj Silver?

To contact Aj Silver send an email to [email protected] or [email protected]. If you want to call Aj Silver try calling on 5084501376. (updated on October 14, 2025)

What company does Aj Silver work for?

Aj Silver works for CRISPR Therapeutics.

What is Aj Silver's role at CRISPR Therapeutics?

Aj Silver is Senior Vice President Finance

What industry does Aj Silver work in?

Aj Silver works in the Biotechnology industry.

Find anyone, anywhere
with ContactOut today

Making remote or global hires? Connecting
with key decision-makers? We can help.

  • 40 emails / month
  • 3 phone numbers / month
  • Works on standard LinkedIn only
  • Work emails, personal emails,
    mobile numbers
* 1 user per company limit

No credit card required

Try ContactOut for Free